Sep 14, 2018 • 8:05 am EDT Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting
Aug 23, 2018 • 8:05 am EDT Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference
Aug 8, 2018 • 9:00 am EDT Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update
Jul 25, 2018 • 9:20 am EDT Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
Jul 20, 2018 • 9:20 am EDT Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
Jun 21, 2018 • 8:00 am EDT Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference
Jun 14, 2018 • 8:25 am EDT Corbus Pharmaceuticals to Present at the JMP Securities Life Science Conference
Jun 13, 2018 • 9:29 am EDT Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018
Jun 6, 2018 • 7:05 am EDT Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors
May 24, 2018 • 8:00 am EDT Corbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference